The charges deliver on threats the president made last fall to impose 100% tariffs on branded or patented medicines unless companies move production to the U.S.
After decades of pursuing supply chain efficiency, U.S. companies have turned their focus to what’s politely termed “resilience,” but might better be described as redundancy.
Jay Cho, managing director of tariffs and customs at Aprio, advises what importers should (and should not) be doing right now to prepare for duty refunds.
Should importers wait for tariff refunds, or sell the claims to investors for early reimbursement? Tony Gulotta, principal and practice leader with the Ryan tax firm, lays out the considerations.
Currency fragmentation, commodity risk and geopolitical tension are now a connected risk vector. They don’t move sequentially; they amplify each other,